Researchers used an interdisciplinary approach incorporating phylogenetics, 3D protein modeling, and plasmid design to identify and computationally design an antigen representing the core of most currently known sarbecoviruses.
Researchers conducted the phase 1 trial of orally-administered senolytic therapy comprising quercetin (Q) and dasatinib (D) for symptomatic and early-stage Alzheimer's disease (AD) patients.